BOTANIX PHARMACEUTICALS LTD — Capital/Financing Update 2024

Jan 14, 2024

==> picture [114 x 50] intentionally omitted <==

15 January 2024

ASX Market Announcements Office ASX Compliance Pty Ltd Level 40, Central Park 152-158 St Georges Terrace Perth WA 6000

Dear Sir/Madam,

NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)

Botanix Pharmaceuticals Limited (ASX: BOT, Botanix or the Company ) advises that it has today issued 8,214,097 new fully paid ordinary shares ( New Shares ) on exercise of 8,214,097 unlisted options exercisable at $0.09 each and expiring on 12 March 2024. An Appendix 2A for the issue was released to market today.

The Company hereby provides notification under section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Corporations Act ) of the issue of the New Shares. The Corporations Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Corporations Act. By the Company giving this notice ( Notice ), a sale of the New Shares will fall within the exemption in section 708A(5) of the Corporations Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Corporations Act, the Company gives notice that:

• (a) the Company issued the New Shares without disclosure to investors under Part 6D.2 of the Corporations Act;

• (b) this Notice is being given under section 708A(5)(e) of the Corporations Act;

• (c) as at the date of this Notice, the Company has complied with:

  • (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

  • (ii) sections 674 and 674A of the Corporations Act; and

• (d) as at the date of this Notice, there is no excluded information, within the meanings of section 708A(7) and 708A(8) of the Corporations Act.

By order of the Board

==> picture [83 x 45] intentionally omitted <==

Susan Park Company Secretary

1

==> picture [113 x 50] intentionally omitted <==

Release authorised by the Board of Directors.

For more information, please contact:

General enquiries

Investor enquiries

Corporate Communications Hannah Howlett Botanix Pharmaceuticals WE Communications P: +61 8 6555 2945 P: +61 450 648 064 investors@botanixpharma.com hhowlett@we-worldwide.com

Media enquiries Haley Chartres H^CK P: +61 423 139 163 haley@hck.digital

2